Icure Pharmaceutical (XKRX:175250) LT-Debt-to-Total-Asset : 0.04 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Icure Pharmaceutical LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Icure Pharmaceutical's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.04.

Icure Pharmaceutical's long-term debt to total assets ratio increased from Dec. 2023 (0.03) to Dec. 2024 (0.04). It may suggest that Icure Pharmaceutical is progressively becoming more dependent on debt to grow their business.

Icure Pharmaceutical LT-Debt-to-Total-Asset Historical Data

The historical data trend for Icure Pharmaceutical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icure Pharmaceutical LT-Debt-to-Total-Asset Chart

Icure Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.21

0.14

0.03

0.04

Icure Pharmaceutical Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.03	0.03	0.04	0.04

Icure Pharmaceutical LT-Debt-to-Total-Asset Calculation

Icure Pharmaceutical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	5481.432	/	132883.281
	=	0.04

Icure Pharmaceutical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	5481.432	/	132883.281
	=	0.04

Icure Pharmaceutical (XKRX:175250) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Icure Pharmaceutical LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Icure Pharmaceutical's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Icure Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Icure Pharmaceutical Inc (XKRX:175250) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

7, Saimdang-ro 1-gil, Seocho-gu, Seoul, KOR

Website

https://www.icure.co.kr

Icure Pharmaceutical Inc operates as a biopharmaceutical company engages in the development and commercialization of novel transdermal drug delivery formulation. It also developed and commercialized various patches and hydrogels for the treatment of rheumatic arthritis pain, nicotine replacement therapy, medicated wound dressings, skin care, and dental care. The products pipeline is also aimed at the development of prescription drugs to diseases of the central nervous system, asthma, and pain.

Icure Pharmaceutical Headlines

No Headlines